ACCELERATE: No reduction of major CV events with CETP inhibition

Media formats available:

No improvements in CV outcomes at 90 days with human ApoA-1 infusions post-MI
No improvements in CV outcomes at 90 days with human ApoA-1 infusions post-MI
ACC.24
No improvements in CV outcomes at 90 days with human ApoA-1 infusions post-MI
- Michael Gibson, MD
Characteristics of patients with DM using icosapent ethyl in the real world
Characteristics of patients with DM using icosapent ethyl in the real world
Dyslipidemia
Characteristics of patients with DM using icosapent ethyl in the real world
- Om P. Ganda, MD
The effect of icosapent ethyl on CV events in metabolic syndrome
The effect of icosapent ethyl on CV events in metabolic syndrome
Diabetes
The effect of icosapent ethyl on CV events in metabolic syndrome
- Michael Miller, MD
Understanding the working mechanism of EPA
Understanding the working mechanism of EPA
Dyslipidemia
Understanding the working mechanism of EPA
- Preston Mason, PhD

PACE-CME